This chronic disorder associated with pruritus usually starts in infancy and presents with dry skin, eczematous lesions and lichenification. It is believed that AD is associated with other IgE associated disorders like allergic rhinitis, asthma, and food allergies. AD has significant morbidity and it appears that the prevalence of the disorder has been increasing over the past few decades.
Atopic dermatitis has a complex etiology including genetic and environmental factors which lead to abnormalities in the epidermis and the immune system. Atopic dermatitis is part of the atopic triad (atopic dermatitis, allergic rhinoconjunctivitis, and asthma) which may start simultaneously or in succession in what is known as the "atopic march." Patients with the atopic triad have a defective barrier of the skin, upper respiratory, and lower respiratory tract which leads to their symptomatology. If one parent is atopic, there is more than a 50% chance that their offspring will develop atopic symptoms. If both parents are affected, up to 80% of offspring will be affected. Genetic alterations include loss of function mutations of filaggrin (Filament Aggregating Protein), an epidermal protein that is broken down into natural moisturization factor. Filaggrin mutations are present in up to 30% of atopic dermatitis patients and may also predispose patients to ichthyosis vulgaris, allergic rhinitis, and keratosis pilaris. Food hypersensitivity may also cause or exacerbate atopic dermatitis in 10% to 30% of patients. Ninety percent of such reactions or flares are caused by eggs, milk, peanuts, soy, and wheat.
Recent studies indicate that there may be an association between smoking and adult-onset AD.
Atopic dermatitis is seen in approximately 10% to 30% of children and 2% to 10% of adults in developed countries. This prevalence has increased two to three-fold in recent decades. Atopic dermatitis has a higher incidence at higher latitudes, which may be related to decreased sun exposure and lower humidity levels. Atopic dermatitis is divided into three subsets based on the age of onset:
Atopic dermatitis patients have a defective skin barrier that is susceptible to xerosis and environmental irritants and allergens that lead to inflammation, pruritus, and the classic clinical findings of atopic dermatitis. The barrier defect may be caused in part by decreased levels of ceramides, which are sphingolipids in the stratum corneum which play a role in the skin's barrier function and prevent transepidermal water loss. The defective skin barrier allows irritants and allergens to penetrate the skin and cause inflammation via an overactive Th2 response (with increased IL-4, IL-5 cytokines) in acute lesions and Th1 response (with IFN-gamma and IL-12) in chronic lesions. Scratching of the skin also stimulates keratinocytes to release inflammatory cytokines such as TNF-alpha, IL-1, and IL-6. Decreased anti-microbial peptides (human beta-defensins, cathelicidins) in the epidermis of atopic patients also contribute to Staphylococcus aureus colonization seen in more than 90% of atopic dermatitis patients. S. aureus may worsen the inflammation of atopic dermatitis lesions and lead to secondary infection and impetiginization. 
In AD, there is significant water loss across the epidermis, but why there is dysregulation of the epithelial barrier is not fully understood. It is believed that filaggrin, which is critical for epithelial integrity, may be dysfunctional.
A practitioner should take a patient's history and focus on the following:
Classic physical exam findings depend on age group. Infants develop edematous papules and plaques that may have vesicles or crust on the scalp, face, and extensor extremities. Infants rarely have atopic dermatitis lesions affecting the diaper area but may be susceptible to other causes of diaper dermatitis such as candida or seborrheic dermatitis. Atopic dermatitis children classically have less exudative patches and plaques on antecubital and popliteal fossae; adults have chronic lichenified (enhanced skin markings) lesions that have a predilection for hands. Individual lesions may also be further classified into acute (edematous, erythematous papules and plaques and/or vesicles/crusting), subacute (erythema, scale, variable crusting), or chronic (thick plaques with lichenification and scale) stages.
Atopic dermatitis is typically a clinical diagnosis given the classic distribution of lesions in each age group. The presence of associated findings (e.g., keratosis pilaris) may facilitate diagnosis. A biopsy will show an eczematous pattern. In childhood cases that are recalcitrant to treatment, fluorescent enzyme immunoassays or skin prick testing can be performed to detect immunoglobulin E (IgE) antibodies against specific allergens, which may or may not be a clinically relevant exacerbating factor.
The four major components of treatment include trigger avoidance, daily skin care, anti-inflammatory therapy, and other complementary modalities.
Daily skin care includes the application of emollients twice daily, with the application within three minutes of exiting lukewarm shower or bath to prevent skin drying. Ointments are the most occlusive but may be more greasy. Topical steroids, which should be applied before emollients to "lock-in" their effect, are first-line agents for acute flares. The potency should be strong enough to control a flare quickly, and consideration should be given for tapering every other day and for maintenance therapy twice weekly (e.g., weekends) in the usual areas of involvement. Reversible side effects of steroid use include skin atrophy and telangiectasia.
Sensitive areas (including the intertriginous areas of the axilla and groin, in addition to the face) may require topical nonsteroidal agents including calcineurin inhibitors such as tacrolimus and pimecrolimus. Newer non-steroidal agents include crisaborole, which exerts its effect by blocking PDE-4. When atopic dermatitis is not controlled with topical agents, systemic agents include phototherapy (ultraviolet (UV) A, UVB, and narrow-band UVB), cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate.
A newly FDA-approved biologic therapy is dupilumab, which is a monoclonal antibody that blocks the IL-4 receptor and thus the effect of IL-4 and IL-13. Other complementary therapies include bleach baths (0.5 cup bleach in full 40 gallon tub) one to two times weekly to decrease S. aureus colonization, low allergen maternal diets during breastfeeding, and probiotic and prebiotic use in pregnant mothers and at-risk infants which has shown 50% decreased frequency of atopic dermatitis at ages 1 to 4 years old compared to placebo.
Recently Crisaborole topic ointment was approved for mild to moderate AD. The drug is a phosphodiesterase inhibitor and shown to improve skin symptoms.
Some patients may benefit from probiotics; it is believed that the bacterial products may enhance the immune system and prevent the development of allergic IgE antibody response. Further, probiotics are recommended during pregnancy and in breast feeding women.
Numerous studies show that bleach baths may help relieve the symptoms of AD by lowering the risk of superinfection with bacteria.
Guidelines on the use of cyclosporine
Overall, many patients with AD do improve with time. However, at the same time patients with AD may also have allergic rhinitis and asthma, which may not improve. In most cases of childhood-onset AD, the disorder persists for decades. The condition has relapses and remissions; relapses often require the use of medications. Individuals who are continuously exposed to smoke, tobaccos, pet dander, fumes, pollen, soap, detergent, and wool will have continual symptoms and the overall quality of life is poor.
Persistent and recurrent itching not only is irritating but is costly to manage. A well-known complication of AD is Kaposi varicelliform eruption, that is linked to a primary herpes infection. The vesicular lesions appear in the eczematous area and can quickly spread to healthy skin. Treatment with acyclovir can help lower the morbidity.
Patients with AD are also prone to skin infections with Staphylococcus and streptococcus.
Patients should wear cotton garments and avoid wool. In addiion, the temperature in the home should be on the cooler side as it may help decrease sweating and itching. A humidifier is recommended to prevent drying of the skin. Foods that trigger AD symptoms should be avoided.
Treatment and management of atopic dermatitis should start with education of the patient and/or parents of the chronic nature of the disease and importance of maintenance therapy, which improves the epidermal barrier and prevents sensitization to allergens and possible prevention of atopic dermatitis.
Atopic dermatitis is a chronic skin disorder that can adversely affect the quality of life. While the condition can be managed with medical therapy, there are also non-medical remedies that can make a big difference in the quality of life. Both the pharmacist and nurse can play a vital role in educating the patient on nonmedical remedies to manage atopic dermatitis. The patient should be educated on wearing soft clothing- preferably cotton and avoid wool. The home temperatures should be kept low because the heat can cause sweating and exacerbation of the irritation. A humidifier should be used to prevent dryness in the home. All garments should be washed with a mild detergent with no fabric softener or bleach. When going outdoors, ample sunscreen and moisturizer should be applied. The patient should keep a diary of all the foods and avoid foods that trigger the attacks. The patient should avoid activities that cause excess diaphoresis. Finally, patients who have asthma should be compliant with their medications and avoid allergens. (level II)
The majority of patients with atopic dermatitis do improve with age. About 30% of patients will develop allergic rhinitis, and 30% will develop asthma. A long-term study that evaluated patients with Atopic Dermatitis indicates that mild to moderate symptoms often persist for a decade or more. And about 80% of these patients will need topical medications to control the symptoms. Symptoms relief is usually seen after the 2nd decade of life, but this also means a drastic change in lifestyle that includes avoiding all triggers like tobacco, pet dander, wool, and certain soaps. Atopic dermatitis may not be life-threatening, but it can seriously affect the quality of life. The constant dryness and itching of skin not only leads to a high financial burden and often requires multiple hospital visits. (Level V)
|||Paller A,Jaworski JC,Simpson EL,Boguniewicz M,Russell JJ,Block JK,Tofte S,Dunn JD,Feldman SR,Clark AR,Schwartz G,Eichenfield LF, Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. American journal of clinical dermatology. 2018 Aug 30 [PubMed PMID: 30168085]|
|||Giavina-Bianchi M,Giavina-Bianchi P, Systemic Treatment for Severe Atopic Dermatitis. Archivum immunologiae et therapiae experimentalis. 2018 Aug 22 [PubMed PMID: 30159581]|
|||Drucker AM,Ellis A,Jabbar-Lopez Z,Yiu ZZN,Arents BWM,Burton T,Spuls PI,Küster D,Schmitt J,Flohr C, Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. BMJ open. 2018 Aug 29 [PubMed PMID: 30158235]|
|||Oliveira ADT,Sodré CS,Ferreira DC,Abad ED,Saintive S,Ribeiro M,Cavalcante FS,Piciani B,Gonçalves LS, Oral Aspects Identified in Atopic Dermatitis Patients: A Literature Review. The open dentistry journal. 2018 [PubMed PMID: 29988222]|
|||Berg AK,Nørgaard K,Thyssen JP,Zachariae C,Hommel E,Rytter K,Svensson J, Skin Problems Associated with Insulin Pumps and Sensors in Adults with Type 1 Diabetes: A Cross-Sectional Study. Diabetes technology [PubMed PMID: 29893593]|
|||Murota H,Yamaga K,Ono E,Katayama I, Sweat in the pathogenesis of atopic dermatitis. Allergology international : official journal of the Japanese Society of Allergology. 2018 Aug 3 [PubMed PMID: 30082151]|
|||Hulshof L,Overbeek SA,Wyllie AL,Chu MLJN,Bogaert D,de Jager W,Knippels LMJ,Sanders EAM,van Aalderen WMC,Garssen J,Van't Land B,Sprikkelman AB, Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis. Frontiers in immunology. 2018 [PubMed PMID: 29966024]|
|||Sung CT,McGowan MA,Jacob SE, Allergic Contact Dermatitis Evaluation: Strategies for the Preschooler. Current allergy and asthma reports. 2018 Aug 1 [PubMed PMID: 30069607]|
|||Batmaz SB, Laboratory and severity evaluation of pediatric atopic dermatitis and moisturizer response in different phenotypes. Allergologia et immunopathologia. 2018 Jul 3 [PubMed PMID: 29980402]|
|||Ariëns LFM,Bakker DS,van der Schaft J,Garritsen FM,Thijs JL,de Bruin-Weller MS, Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Therapeutic advances in chronic disease. 2018 Sep [PubMed PMID: 30181845]|
|||Ali Z,Ulrik CS,Agner T,Thomsen SF, Association between Atopic Dermatitis and the Metabolic Syndrome: A Systematic Review. Dermatology (Basel, Switzerland). 2018 [PubMed PMID: 30110673]|
|||Wollenberg A,Barbarot S,Bieber T,Christen-Zaech S,Deleuran M,Fink-Wagner A,Gieler U,Girolomoni G,Lau S,Muraro A,Czarnecka-Operacz M,Schäfer T,Schmid-Grendelmeier P,Simon D,Szalai Z,Szepietowski JC,Taïeb A,Torrelo A,Werfel T,Ring J, Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. Journal of the European Academy of Dermatology and Venereology : JEADV. 2018 Jun [PubMed PMID: 29878606]|
|||Rastogi S,Patel KR,Singam V,Silverberg JI, Allergic Contact Dermatitis To Personal Care Products And Topical Medications In Adults With Atopic Dermatitis. Journal of the American Academy of Dermatology. 2018 Jul 24 [PubMed PMID: 30053491]|
|||Thomas KS,Bradshaw LE,Sach TH,Cowdell F,Batchelor JM,Lawton S,Harrison EF,Haines RH,Ahmed A,Dean T,Burrows NP,Pollock I,Buckley HK,Williams HC,Llewellyn J,Crang C,Grundy JD,Guiness J,Gribbin A,Wake EV,Mitchell EJ,Brown SJ,Montgomery AA, Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health technology assessment (Winchester, England). 2017 Apr [PubMed PMID: 28409557]|
|||Napolitano M,Marasca C,Fabbrocini G,Patruno C, Adult atopic dermatitis: new and emerging therapies. Expert review of clinical pharmacology. 2018 Aug 9 [PubMed PMID: 30073901]|